Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Prospective, Real World, National Study to Assess the Efficacy and Safety of Adjuvant Biosimilar Tratuzumab (Zedora) Treatment in Patients With Localized Her2 Positive Breast Cancer

NCT03892655 is registered in ClinicalTrials.gov with Libbs Farmacêutica LTDA as lead sponsor.

NCT NCT03892655
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03892655 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Prospective, Real World, National Study to Assess the Efficacy and Safety of Adjuvant Biosimilar Tratuzumab (Zedora) Treatment in Patients With Localized Her2 Positive Breast Cancer
Lead sponsor
Libbs Farmacêutica LTDA
Phase
Observational
Overall status
Active, not recruiting
Start date
October 7, 2019
Completion date
July 31, 2028
Enrollment
170 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer